论文部分内容阅读
目的:评价参附注射液治疗急性下壁右室心肌梗死合并低血压状态病人的疗效及安全性。方法:总结我院2014年1月—2016年12月急性下壁右室心肌梗死合并低血压状态病人50例,其中参附组(实验组)25例,多巴胺组(对照组)25例,观察其临床疗效。结果:两组用药后血压回升明显。治疗组升压总有效率为96%,对照组升压总有效率为88%,不良反应发生率在两组之间无明显差异。BNP和CRP的下降幅度实验组大于对照组。结论:参附注射液在治疗急性下壁右室心肌梗死合并低血压状态的患者中效果明显,无副反应发生。
Objective: To evaluate the efficacy and safety of Shenfu Injection in the treatment of patients with acute inferior wall right ventricular myocardial infarction complicated with hypotension. Methods: From January 2014 to December 2016, 50 patients with acute inferior wall myocardial infarction complicated with hypotension were enrolled in this study. Among them, 25 cases were treated with Shenfu (experimental group) and 25 cases were treated with dopamine (control group) Its clinical efficacy. Results: Two groups of blood pressure rise significantly after treatment. The total effective rate of the treatment group was 96%, the total effective rate of the control group was 88%, the incidence of adverse reactions in the two groups no significant difference. The decline of BNP and CRP in the experimental group was larger than that in the control group. Conclusion: Shenfu injection in the treatment of acute inferior wall myocardial infarction with hypotension in patients with obvious effect, no side effects.